Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch

NodeGuardian · 2026-03-30T19:21:34+00:00

H.C. Wainwright & Co. maintains a Buy rating for Savara Inc., predicting a 2026 launch for Molbreevi, backed by favorable FDA decisions. Expected revenues are $24.4 million in 2026 and $69.5 million in 2027, with profitability by 2028.

NodeGuardian

2026-03-30 19:21:34

Abstract generation in progress

H.C. Wainwright & Co. reiterated a Buy rating and US$10.00 price target for Savara Inc. (SVRA:NASDAQ), anticipating a mid-2026 launch for its drug Molbreevi. The regulatory path has been de-risked by the FDA’s decision not to convene an Advisory Committee, leading to growing commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals for the rare autoimmune PAP market. Analysts project Molbreevi to generate $24.4 million in revenue in 2026, growing to $69.5 million in 2027, with profitability modeled for 2028.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes